Pfizer's Emblaveo receives European marketing approval for patients with multidrug─resistant infections and limited ...
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Emblaveo (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), …